Professor @OHSUKnight, A team of motivated scientists studying microenvironmental regulation of pre-leukemic and leukemic cells
Portland, Oregon
Joined December 2019
- Tweets1.1K
- Following387
- Followers799
- Likes5.6K
Pinned Tweet
We are looking for motivated scientists to join our team @OHSUKnight for a postdoctoral position with Experience in cell signaling & cancer biology to study inflammation role in leukemia evolution. Interested candidates DM/apply👇#Academia #postdoc, #phd Pl spread the words
Anupriya Agarwal Lab retweeted
Happy to help lead this study here at @OHSUKnight for our patients and families.
Excited to share that our low-dose Sirolimus study for Adults with RUNX1-FPD is now enrolling @OHSUNews. Thanks for partnership: @OHSUKnight, @CLachowiez, Dr. DiNardo, @RUNX1Research @AmericanCancer. Pl share with eligible individuals. https:/clinicaltrials.gov/study/NCT07844694
Excited to share that our low-dose Sirolimus study for Adults with RUNX1-FPD is now enrolling @OHSUNews. Thanks for partnership: @OHSUKnight, @CLachowiez, Dr. DiNardo, @RUNX1Research @AmericanCancer. Pl share with eligible individuals. https:/clinicaltrials.gov/study/NCT07844694
The low-dose sirolimus pilot study has expanded to @OHSUNews in Portland, with a limited number of additional spots also available at @UTMDAnderson. The expansion follows encouraging early observations among the first participants.
Adults with a confirmed pathogenic or likely pathogenic germline RUNX1 variant, a platelet count of at least 50,000/µL, and no prior diagnosis of MDS or another blood cancer may be eligible. Additional eligibility requirements apply.
Please share with your potentially eligible patients.
Learn more: runx1researchprogram.org/xSi…
Anupriya Agarwal Lab retweeted
Since 2017, RRP has funded and co-funded more than 30 investigators at institutions across the world working to better understand RUNX1-FPD and prevent blood cancer.
None of it happens without community support. As we continue to fund the next generation of research, your donation helps keep this work moving forward.
100% of donations go directly to funding this research: runx1researchprogram.org/xDo…
Anupriya Agarwal Lab retweeted
Now enrolling: a pilot clinical trial at @UTMDAnderson evaluating low-dose sirolimus (rapamycin) in individuals with RUNX1-FPD.
The study’s primary objective is to assess safety and tolerability. The scientific rationale is based on whether mTORC1 pathway inhibition may support hematopoietic health and potentially reduce blood cancer risk in RUNX1-FPD.
Clinicians are encouraged to review and refer eligible patients here for more information: runx1researchprogram.org/xSi…
Anupriya Agarwal Lab retweeted
Paying peer reviewers led to faster first editorial decisions — an average of 5.5 working days, down from nearly 38 for unpaid reviews.
The review quality, as judged by handling editors on the basis of helpfulness in making an editorial decision, went up.
1/
Anupriya Agarwal Lab retweeted
At @theNCI, our mission is simple: reduce the burden of cancer.
That means moving faster—from discovery to patient impact—and doing it together.
Follow along as we work to drive the next generation of breakthroughs.
Great mentor and amazing science 🧬
We are actively recruiting a postdoctoral fellow to join our lab @jacksonlab! 😎 Details and link to apply: thejacksonlaboratory.wd503.m…
Anupriya Agarwal Lab retweeted
We are actively recruiting a postdoctoral fellow to join our lab @jacksonlab! 😎 Details and link to apply: thejacksonlaboratory.wd503.m…
I am honored to receive this grant @OHSUKnight for sirolimus trial in RUNX1-FPD & thankful to @RUNX1Research @ACSNews collaborators Dr. DiNardo @CLachowiez Dr.Lucero, @KellyLBolton Drs. Cantor & Frelinger, patients/families to support our mission of early intervention/prevention
We’re proud to co-fund a new $1.89M LEAP Grant with @AmericanCancer to support an expanded clinical trial at @OHSUKnight and @LabAgarwal.
The study is evaluating a low dose of sirolimus in individuals with RUNX1-FPD to determine safe dosing, an important step in ongoing research toward #bloodcancer prevention and intervention for this high-risk community.
Read more: news.ohsu.edu/2026/04/07/ohs…
I am honored to receive this grant for sirolimus trial in RUNX1-FPD @ACSNews @RUNX1Research & thanks to collaborators Dr. DiNardo @UTMDAnderson @CLachowiez Dr.Lucero, @KellyLBolton Drs. Cantor & Frelinger, patients/families to support our mission of early intervention/prevention
A new award will enable researchers at @OHSUNews to test an anti-inflammatory drug for patients at heightened risk of developing leukemia due to an inherited mutation in the RUNX1 gene.
@LabAgarwal will serve as the principal investigator at OHSU: news.ohsu.edu/2026/04/07/ohs…
Anupriya Agarwal Lab retweeted
📣 Save the Date | Oregon Drug Discovery Symposium (ODDS) 2026
The symposium takes place April 8–9, 2026, and will feature scientific talks, discussions, and a poster session, providing a forum for knowledge exchange across disciplines.
Register: bit.ly/4qbMRU0
ALT Drs. Sanjay Malhotra (L) and Shivaani Kummar (R) pose for an image while wearing their white research lab coats inside an OHSU facility.
Anupriya Agarwal Lab retweeted
Join us for Knight School to learn about the latest advances in cancer early detection, including clinical trials and early detection blood tests.
📍 Knight Cancer Research Building
⌚️ 5:30 pm
🗓️ March 31
🎟️ FREE
bit.ly/40TzeOI
Anupriya Agarwal Lab retweeted
The National Cancer Advisory Board meets March 16–17. NCAB helps shape NCI’s research priorities and funding decisions, guiding the direction of our nation’s cancer efforts. I encourage you to join the open session via videocast and stay engaged.
cancer.gov/about-nci/advisor…
#NCAB
Merry Christmas🎄& Happy Holidays to all from @LabAgarwal @OHSUKnight. Despite of challenging year we had lots of exciting things- new publications, grants, & celebrations. Thanks to our resilient team & support from friends, family & science community, looking forward to 2026💕
Anupriya Agarwal Lab retweeted
New preprint: teaching single-cell foundation models to learn from perturbations in collaboration with @madduri & @RUNX1Research supported by @cziscience.
Closing the loop identified a target for RUNX1-FPD now in Ph2 trials
🔗biorxiv.org/content/10.1101/…
🧵by @yash_persh👇
Anupriya Agarwal Lab retweeted
A new preprint led by @AlexBickMDPhD, @madduri, and @yash_pershad, with co-authors including @LabAgarwal and RRP’s @EricsonKatrin, uses a closed-loop #AI system to identify and validate therapeutic targets for RUNX1-FPD.
One of these targets, mTOR, supports earlier findings by Dr. Agarwal that led to the ongoing sirolimus clinical trial for RUNX1-FPD patients led by Dr. Courtney DiNardo at @MDAndersonNews: runx1-fpd.org/patient-resear…
A powerful example of how science, AI, and #patientadvocacy can come together to advance clinical progress!
New preprint: teaching single-cell foundation models to learn from perturbations in collaboration with @madduri & @RUNX1Research supported by @cziscience.
Closing the loop identified a target for RUNX1-FPD now in Ph2 trials
🔗biorxiv.org/content/10.1101/…
🧵by @yash_persh👇
Congratulations 🎊
Congratulations to Dr. @tanaya_shree on being named an @ASH_hematology Basic/Translational Research Junior Faculty scholar recipient!
Funding is awarded to hematologists who conduct research advancing the understanding and treatment of blood disorders: bit.ly/3E4mDjL
ALT Portrait of Tanaya Shree, M.D., Ph.D., smiling in front of a scenic background with a cable car and mountain, with OHSU logo at lower right corner.
Excited to share our latest contribution describing the role of inflammation in regulating defective hematopoiesis in RUNX1-familial platelet disorder & identifying CD74/mTORC/JAK axis as one of the drivers of inflammation @ScienceTM @OHSUKnight @OHSUNews
science.org/doi/10.1126/scit…
Thanks to our RUNX1-FPD patient community for sharing precious samples, collaborators, NIH team, & Mona for extraordinary efforts for helping to bring story together as her thesis & support from @RUNX1Research @nih_nhlbi @NCICancerCtrl @EdwardPEvansFdn @ALSFNews & @ScienceTM Team
The work led to opening of a unique clinical trial at MD Anderson Cancer Center in collaboration with @OHSUKnight led by Dr. Courtney DiNardo “Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder” clinicaltrials.gov/study/NCT…